GE Healthcare’s acquisition of Asymptote Limited, a specialists in cryochain technology for sensitive cellular therapies


GE Healthcare has acquired Asymptote Limited, specialists in cryochain technology for sensitive cellular therapies.

Asymptote’s integrated suite of cryochain hardware, software and consumables are designed to maintain the potency of cellular therapies enabling ultra-low temperature freezing during production, all the way to thawing at the clinic prior to administering to patients.

The acquisition of Asymptote fills a critical gap in GE Healthcare’s end-to-end ecosystem of products and services for cell therapy production, and will be an important piece of the portfolio enabling the industrialization of these life-saving therapies.

Cellular therapies are rapidly changing the healthcare landscape by providing life-saving and potentially curative treatments for many of the world’s most challenging diseases, especially cancer. The cell therapy oncology market alone is expected to reach $30 billion by 2030 with almost 800 potentially life-changing therapies in clinical trials at the end of 2016.

Jones Day has advised General Electric in the acquisition by subsidiary GE Healthcare of Asymptote Limited, with a team led by partner Leon Ferera.

Involved fees earner: Leon Ferera – Jones Day;

Law Firms: Jones Day;

Clients: General Electric (GE);

Print Friendly, PDF & Email